HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bryan T H Koh Selected Research

Neoplasms (Cancer)

1/2023Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.
1/2022Pan-cancer pervasive upregulation of 3' UTR splicing drives tumourigenesis.
1/2018Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bryan T H Koh Research Topics

Disease

3Neoplasms (Cancer)
01/2023 - 01/2018
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2023
1Hepatocellular Carcinoma (Hepatoma)
01/2022
1Colonic Neoplasms (Colon Cancer)
01/2022
1Leukemia
01/2020
1Multiple Myeloma
01/2018
1Rupture
06/2016
1Anterior Cruciate Ligament Injuries
06/2016

Drug/Important Bio-Agent (IBA)

3RNA (Ribonucleic Acid)IBA
01/2023 - 01/2018
1Adenosine (Adenocard)FDA LinkGeneric
01/2023
1EnzymesIBA
01/2023
1Core Binding Factors (Core-Binding Factor)IBA
01/2023
1InosineFDA Link
01/2023
13' Untranslated Regions (3' UTR)IBA
01/2022
1Deubiquitinating EnzymesIBA
01/2020
1DNA (Deoxyribonucleic Acid)IBA
01/2018

Therapy/Procedure

1Therapeutics
01/2022
1Anterior Cruciate Ligament Reconstruction
06/2016